3rd Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference

January 22-24, 2020

Sponsor Guide

Follow the conference on Twitter!

Gulf Coast Consortia

QUANTITATIVE BIOMEDICAL SCIENCES

The Gulf Coast Consortia (GCC), located in Houston, Texas, is a dynamic, multi-institution collaboration of basic and translational scientists, researchers, clinicians and students in the quantitative biomedical sciences, who benefit from joint training programs, topic-focused research consortia, shared facilities and equipment, and exchange of scientific knowledge. Working together, GCC member institutions provide a cutting-edge collaborative training environment and research infrastructure beyond the capability of any single institution. GCC training programs currently focus on Biomedical Informatics, Computational Cancer Biology, Molecular Biophysics, Neuroengineering, Pharmacological Sciences, Precision Environmental Health Sciences and Antimicrobial Resistance. GCC research consortia gather interested faculty around research foci within the quantitative biomedical sciences, and currently include Antimicrobial Resistance, Nanox, Mental Health, Innovative Drug Discovery and Development, Translational Pain Research, Theoretical and Computational Neuroscience, Single Cell Omics, Regenerative Medicine, Translational Imaging and Cellular and Molecular Biophysics. Current members include Baylor College of Medicine, Rice University, University of Houston, The University of Texas Health Science Center at Houston, The University of Texas Medical Branch at Galveston, The University of Texas M. D. Anderson Cancer Center, and the Institute of Biosciences and Technology of Texas A&M Health Science Center.

GCC for Antimicrobial Resistance Executive Steering Committee

Cesar Arias, UTHealth, Chair

Ashok Chopra, UTMB
Kevin Garey, UH
Magnus Hook, TAMHSC IBT
Julian Hurdle, TAMHSC IBT
Tim Palzkill, BCM
Trish Perl, UTSW
George Phillips, Rice U.

Lynn Zechiedrich, BCM, Co-Chair

Adriana Rosato, HMRI
Tor Savidge, BCM
Ed Septimus, Harvard Med. School & TAMU
Yousif Shamoo, Rice U.
Samuel Shelburne, MDACC
Suzanne Tomlinson, GCC
Vincent Tam, UH

UTHealth The University of Texas Health Science Center at Houston | McGovern Medical School

Center for Antimicrobial Resistance and Microbial Genomics

Center for Antimicrobial Resistance and Microbial Genomics (CARMiG)

MISSION

The Mission of the Center for Antimicrobial Resistance and Microbial Genomics is to develop a comprehensive research and educational program to study the complex factors that contribute to the development of resistance and create an environment where specific actions can be taken to tackle this important public health problem. We seek to develop research in a variety of areas that involve, i) mechanisms of antimicrobial resistance, ii) epidemiology of antibiotic resistance organisms, iii) clinical impact of antibiotic resistance, iv) antibiotic stewardship and iv) the influence of antibiotic resistance in the environment (including in animals for human consumption). Primarily, we seek to develop innovative clinical and therapeutic approaches to deal with multi-drug resistant organisms.

CORE ACTIVITIES

Clinical and antibiotic stewardship cores – understanding the clinical aspects of antibiotic resistance and launching programs on surveillance, antibiotic stewardship, and interventional studies

Basic science – elucidation of the molecular mechanisms of antibiotic resistance and identification of potentially novel targets for drug discovery

Genomics – performing and analyzing bacterial genome sequencing to develop rapid diagnostic tools, evaluate antimicrobial resistance profiles, and study the molecular epidemiology of resistant pathogens

Pharmacology and animal models – development of animal models to study therapeutics and pharmacological aspects of antibiotics

Training and education – supporting the development of young investigators interested in antimicrobial resistance and launching educational training programs for clinicians and scientists at the graduate, postgraduate, and assistant professor level

Clinical trials – provide the ideal location and expertise to lead and conduct robust, large-scale clinical trials.

For additional information, please visit us at
https://www.carmig.net/

HOUSTON HEALTH DEPARTMENT

As the 4th largest city in the United States and home to the largest medical center in the world, The Houston Health Department has made it a priority to address Healthcare Associated Infections (HAI) and Antibiotic Resistant and Stewardship (AR AS) in the Houston area. This involves a multifaceted approach that entails coordination with members of the healthcare community, public health, academia and other stakeholders. Through a CDC grant awarded to the city, the HAI program has been able to strengthen local capacity to perform epidemiological and laboratory work by detecting, tracking and responding to infectious disease threats. With this funding the program has been able to implement the below activities:

- Participation in the CDC's Antibiotic Resistance and Laboratory Network (ARLN) that involves HHD's laboratory collecting, confirming and characterizing carbapenem resistant isolates. In 2018 HHD's laboratory collected and characterized resistance of 412 Carbapenem resistant Enterobactericae (CRE) and Carbapenem resistant Pseudomonas aeruginosa (CRPA) isolates from facilities within Houston and 16 surrounding counties.
- Responding to investigations of multidrug resistant organisms with a focus on containment and preventing transmission.
- Preforming Infection Control Assessments (ICARs) to identify strengths and mitigate potential infection control gaps in healthcare facilities. Currently HHD's HAI program is working with facilities on identified needs in the areas of 1) staff training in infection prevention and control 2) education in environmental cleaning, injection safety, and PPE and 3) drug expertise in the core elements of antibiotic stewardship.
- Promotion and implementation of CDC's core elements of Antibiotic Stewardship Programs in healthcare facilities. The goal is to develop activities with facilities that reduce adverse events, prevent antimicrobial resistance and produce better outcomes for patients.
- Continue partnering with CARMIG to host its Annual Antimicrobial Resistance and Stewardship Symposium.
- Improving surveillance to drive public health action.
- Coordinated communications and partnerships that focus on developing AR AS activities that will benefit the Houston community.

Thank you to our sponsors:

Platinum:

Allergan

MERCK

Gold:

ALK

Silver:

astellas

Kelsey Research Foundation

Collaborate. Study. Discover.

T2Biosystems®

QIAGEN Inc.

ACCELERATE DIAGNOSTICS™

NUZYRA™ (omadacycline)

Learn what our portfolio of products can do for your patients.

Contact your Allergan representative or call 800-678-1605 for more information.

Brought to you by Allergan, Inc.

Allergan

Allergan® and its design are trademarks of Allergan, Inc.
MONUROL® and its design are registered trademarks of Zambon SpA.
AVYCAZ® and its design are trademarks of Allergan Sales, LLC.
TEFLARO® and its design are registered trademarks of Allergan Sales, LLC.
DALVANCE® and its design are trademarks of Allergan Pharmaceuticals International Limited.
© 2019 Allergan. All rights reserved. MBD124562 05/19

Platinum Sponsor

Gold Sponsor

ALK

Silver Sponsors

QIAstat-Dx

The next generation of syndromic insights

Expanding diagnostic capabilities

- Ct values and amplification curves
- Real-time PCR technology
- Comprehensive and accurate results

Learn more at **QIAstat-Dx.com**

Sample to Insight

QIAGEN

astellas

Antimicrobial stewardship teams around the country are leveraging earlier phenotypic susceptibility results to reinforce their interventions.

How will earlier interventions improve your outcomes?

ACCELERATE *pheno*

axdx.com

Copyright ©2020 Accelerate Diagnostics, Inc. All Rights Reserved. "ACCELERATE DIAGNOSTICS", "ACCELERATE PHENO", "ACCELERATE PHENOTEST" and diamond shaped logos and marks are registered marks of Accelerate Diagnostics, Inc.

Species ID of sepsis-causing pathogens within 3-5 hours of first blood draw.

Shorter time to targeted therapy and de-escalation

www.t2biosystems.com

T2Biosystems®

NUZYRA®
(omadacycline)

J-CODE NOW AVAILABLE

J0121–INJECTION, OMADACYCLINE, 1 MG*

Effective October 1, 2019, NUZYRA was assigned an HCPCS J-Code by Centers for Medicare & Medicaid Services (CMS).

This new HCPCS code can be used for NUZYRA IV claims† with a date of service on or after October 1, 2019.

*Based on lowest divisible dose per infusion (1 mg/mL)

NUZYRA CENTRAL™

For information and support, call ***NUZYRA Central™ Support Services*** at **1-877-4-NUZYRA (1-877-468-9972)**, Mon–Fri, 9 AM to 8 PM ET to speak with a representative.

†By providing this information, Paratek does not guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payer, plan, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims.

PARATEK

© 2019 Paratek Pharmaceuticals, Inc. All rights reserved.
PARATEK® and the hexagon logo are registered trademarks of Paratek Pharmaceuticals, Inc.
NUZYRA® and its design logo are registered trademarks of Paratek Pharmaceuticals, Inc.

US-NUA-0193 08/19

Kelsey Research Foundation

Collaborate. Study. Discover.


Save the date
January 26-28, 2021
4th Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference